Binje Vick

Binje Vick

Auto-generated profile, based on publicly available information

Binje Vick

Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
EYEliza Yankova
Eliza Yankova
WBWesley Blackaby
Wesley Blackaby
MAMark Albertella
Mark Albertella
JRJustyna Rak
Justyna Rak
EBEtienne De Braekeleer
Etienne De Braekeleer
TKTony Kouzarides
Tony Kouzarides

1 December 2017 in Science
Verified
Journal Article
Open access
PDF file
SKSusan Klaeger
Susan Klaeger
SHStephanie Heinzlmeir
Stephanie Heinzlmeir
MWMathias Wilhelm
Mathias Wilhelm
HPHarald Polzer
Harald Polzer
BVBinje Vick
Binje Vick
BKBernhard Kuster
Bernhard Kuster
An atlas for drug interactions: Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. There are hundreds of kinases within the human body, so knowing the kinase “target” of each drug is essential for developing successful treatment strategies. Sometimes clinical trials can fail because drugs bind more than one target. Yet sometimes off-target effects can be beneficial, and drugs can be repurposed for treatment of additional diseases. Klaegeret al.performed a comprehensive analysis of 243 kinase inhibitors that are either approved for use or in clinical trials. They provide an open-access resource of target summaries that could help researchers develop better drugs, understand how existing drugs work, and design more effective clinical trials.Science, this issue p.eaan4368

8 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
NPNora Philipp
Nora Philipp
MKMaryam Kazerani
Maryam Kazerani
ANAlyssa Nicholls
Alyssa Nicholls
BVBinje Vick
Binje Vick
JWJan Wulf
Jan Wulf
Marion SubkleweMarion Subklewe
Marion Subklewe
T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent relapse remains a major challenge. T-cell exhaustion induced by persistent antigen stimulation or tonic receptor signaling has been reported to compromise outcomes of T-cell–based immunotherapies. The impact of continuous exposure to bispecifics on T-cell function, however, remains poorly understood. In relapsed/refractory B-cell precursor acute lymphoblastic leukemia patients, 28-day continuous infusion with the CD19xCD3 bispecific molecule blinatumomab led to declining T-cell function. In an in vitro model system, mimicking 28-day continuous infusion with the half-life–extended CD19xCD3 bispecific AMG 562, we identified hallmark features of exhaustion arising over time. Continuous AMG 562 exposure induced progressive loss of T-cell function (day 7 vs day 28 mean specific lysis: 88.4% vs 8.6%; n = 6; P = .0003). Treatment-free intervals (TFIs), achieved by AMG 562 withdrawal, were identified as a powerful strategy for counteracting exhaustion. TFIs induced strong functional reinvigoration of T cells (continuous vs TFI-specific lysis on day 14: 34.9% vs 93.4%; n = 6; P < .0001) and transcriptional reprogramming. Furthermore, use of a TFI led to improved T-cell expansion and tumor control in vivo. Our data demonstrate the relevance of T-cell exhaustion in bispecific antibody therapy and highlight that T cells can be functionally and transcriptionally rejuvenated with TFIs. In view of the growing number of bispecific molecules being evaluated in clinical trials, our findings emphasize the need to consider and evaluate TFIs in application schedules to improve clinical outcomes.

4 August 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
CKC Krupka
C Krupka
PKP Kufer
P Kufer
RKR Kischel
R Kischel
GZG Zugmaier
G Zugmaier
FLF S Lichtenegger
F S Lichtenegger
Marion SubkleweMarion Subklewe
Marion Subklewe

12 December 2016 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SGStefanie Göllner
Stefanie Göllner
TOThomas Oellerich
Thomas Oellerich
SAShuchi Agrawal-Singh
Shuchi Agrawal-Singh
TSTino Schenk
Tino Schenk
HKHans-Ulrich Klein
Hans-Ulrich Klein
CMCarsten Müller-Tidow
Carsten Müller-Tidow

17 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
DSDana Stenger
Dana Stenger
TSTanja A. Stief
Tanja A. Stief
TKTheresa Kaeuferle
Theresa Kaeuferle
SWSemjon Willier
Semjon Willier
FRFelicitas Rataj
Felicitas Rataj
TFTobias Feuchtinger
Tobias Feuchtinger
Anti-CD19 chimeric antigen receptor (CAR) T cells showed significant antileukemic activity in B-precursor acute lymphoblastic leukemia (ALL). Allogeneic, HLA-mismatched off-the-shelf third-party donors may offer ideal fitness of the effector cells, but carry the risk of graft-versus-host disease. Knockout (KO) of the endogenous T-cell receptor (TCR) in CD19-CAR-T cells may be a promising solution. Here, we induced a CRISPR/Cas9-mediated KO of the TCRβ chain in combination with a second-generation retroviral CAR transduction including a 4-1BB costimulatory domain in primary T cells. This tandem engineering led to a highly functional population of TCR-KO-CAR-T cells with strong activation (CD25, interferon γ), proliferation, and specific killing upon CD19 target recognition. TCR-KO-CAR-T cells had a balanced phenotype of central memory and effector memory T cells. KO of the endogenous TCR in T cells strongly ablated alloreactivity in comparison with TCR-expressing T cells. In a patient-derived xenograft model of childhood ALL, TCR-KO-CAR-T cells clearly controlled CD19+ leukemia burden and improved survival in vivo. However, coexpression of endogenous TCR plus CAR led to superior persistence of T cells and significantly prolonged leukemia control in vivo, confirmed by a second in vivo model using the leukemia cell line NALM6. These results point toward an essential role of the endogenous TCR for longevity of the response at the price of alloreactivity. In conclusion, anti-CD19 CAR T cells with a CRISPR/Cas9-mediated TCR-KO are promising candidates for nonmatched third-party adoptive T-cell transfer with high antileukemic functionality in the absence of alloreactivity, but long-term persistence in vivo is better in the presence of the endogenous TCR.